The intrinsic fusogenicity of glioma cells as a factor of transformation and progression in the tumor microenvironment

International Journal of Cancer

Volumn 131, Issue 2, 2012, Pages 334-343

  Mercapide, Javier ^a   Rappa, Germana ^a   Lorico, Aurelio ^a  

^a NEVADA CANCER INSTITUTE   (United States)

Author keywords

cell fusion; fibronectin; glioma; stroma; tumor progression

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FIBRONECTIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CARCINOGENESIS; CELL ACTIVATION; CELL FUSION; CELL HETEROGENEITY; CELL INTERACTION; CELL LABELING; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DNA CONTENT; EXTRACELLULAR MATRIX; FIBROBLAST; GLIOMA; IMMUNOFLUORESCENCE TEST; MALIGNANT TRANSFORMATION; MOLECULAR DYNAMICS; NUCLEAR REPROGRAMMING; PHENOTYPE; PLOIDY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STROMA; TUMOR MICROENVIRONMENT;

ANIMALS; CELL FUSION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COCULTURE TECHNIQUES; EXTRACELLULAR MATRIX; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; FIBRONECTINS; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HYBRID CELLS; MICE; MITOGEN-ACTIVATED PROTEIN KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84861595384     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26361     Document Type: Article

References (37)

1. Giese A, Westphal M,. Treatment of malignant glioma: a problem beyond the margins of resection. J Cancer Res Clin Oncol 2001; 127: 217-25.
2. Wen PY, Kesari S,. Malignant gliomas in adults. N Engl J Med 2008; 359: 492-507.
3. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI,. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003; 100: 15178-83.
4. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB,. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63: 5821-8.
5. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F, Vescovi A,. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004; 64: 7011-21.
6. Giese A, Westphal M,. Glioma invasion in the central nervous system. Neurosurgery 1996; 39: 235-50.
7. Giese A, Laube B, Zapf S, Mangold U, Westphal M,. Glioma cell adhesion and migration on human brain sections. Anticancer Res 1998; 18: 2435-47.
8. Kaczarek E, Zapf S, Bouterfa H, Tonn JC, Westphal M, Giese A,. Dissecting glioma invasion: interrelation of adhesion, migration and intercellular contacts determine the invasive phenotype. Int J Dev Neurosci 1999; 17: 625-41.
9. Cheng SY, Huang HJ, Nagane M, Ji XD, Wang D, Shih CC, Arap W, Huang CM, Cavenee WK,. Suppression of glioblastoma angiogenicity and tumorigenicity by inhibition of endogenous expression of vascular endothelial growth factor. Proc Natl Acad Sci USA 1996; 93: 8502-7.
10. Hoelzinger DB, Demuth T, Berens ME,. Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J Natl Cancer Inst 2007; 99: 1583-93.
11. Zipori D,. The mesenchyme in cancer therapy as a target tumor component, effector cell modality and cytokine expression vehicle. Cancer Metastasis Rev 2006; 25: 459-67.
12. Kang SG, Shinojima N, Hossain A, Gumin J, Yong RL, Colman H, Marini F, Andreeff M, Lang FF,. Isolation and perivascular localization of mesenchymal stem cells from mouse brain. Neurosurgery 2010; 67: 711-20.
13. Bergfeld SA, DeClerck YA,. Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev 2010; 29: 249-61.
14. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H,. The brain tumor microenvironment. Glia 2011; 59: 1169-80.
15. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006; 9: 157-73.
16. Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, Yoshimoto K, Mischel PS, Cloughesy TF, Liau LM, Nelson SF,. Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res 2006; 4: 607-19.
17. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, Lasorella A, Aldape K, et al. The transcriptional network for mesenchymal transformation of brain tumours. Nature 2010; 463: 318-25.
18. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross JG, Gilbert MR, Phillips HS, et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol 2010; 12: 49-57.
19. Duelli D, Lazebnik Y,. Cell fusion: a hidden enemy? Cancer Cell 2003; 3: 445-8.
20. Pawelek JM, Chakraborty AK,. Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nat Rev Cancer 2008; 8: 377-86.
21. Lu X, Kang Y,. Cell fusion as a hidden force in tumor progression. Cancer Res 2009; 69: 8536-9.
22. Dittmar T, Nagler C, Schwitalla S, Reith G, Niggemann B, Zänker KS,. Recurrence cancer stem cells - made by cell fusion? Med Hypotheses 2009; 73: 542-7.
23. Mercapide J, Rappa G, Anzanello F, King J, Fodstad O, Lorico A,. Primary gene-engineered neural stem/progenitor cells demonstrate tumor-selective migration and antitumor effects in glioma. Int J Cancer 2010; 126: 1206-15.
24. Rappa G, Anzanello F, Alexeyev M, Fodstad O, Lorico A,. Gamma-glutamylcysteine synthetase-based selection strategy for gene therapy of chronic granulomatous disease and graft-vs.-host disease. Eur J Haematol 2007; 78: 440-8.
25. Rappa G, Kunke D, Holter J, Diep DB, Meyer J, Baum C, Fodstad O, Krauss S, Lorico A,. Efficient expansion and gene transduction of mouse neural stem/progenitor cells on recombinant fibronectin. Neuroscience 2004; 124: 823-30.
26. Lorico A, Mercapide J, Solodushko V, Alexeyev M, Fodstad O, Rappa G,. Primary neural stem/progenitor cells expressing endostatin or cytochrome P450 for gene therapy of glioblastoma. Cancer Gene Ther 2008; 15: 605-15.
27. Svensson RU, Barnes JM, Rokhlin OW, Cohen MB, Henry MD,. Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy. Cancer Res 2007; 67: 10445-54.
28. Bjerkvig R, Tysnes BB, Aboody KS, Najbauer J, Terzis AJ,. Opinion: the origin of the cancer stem cell: current controversies and new insights. Nat Rev Cancer 2005; 5: 899-904.
29. Ogle BM, Cascalho M, Platt JL,. Biological implications of cell fusion. Nat Rev Mol Cell Biol 2005; 6: 567-75.
30. Simonavicius N, Robertson D, Bax DA, Jones C, Huijbers IJ, Isacke CM,. Endosialin (CD248) is a marker of tumor-associated pericytes in high-grade glioma. Mod Pathol 2008; 21: 308-15.
31. Harris MA, Yang H, Low BE, Mukherjee J, Guha A, Bronson RT, Shultz LD, Israel MA, Yun K,. Cancer stem cells are enriched in the side population cells in a mouse model of glioma. Cancer Res 2008; 68: 10051-9.
32. Wagner W, Wein F, Seckinger A, Frankhauser M, Wirkner U, Krause U, Blake J, Schwager C, Eckstein V, Ansorge W, Ho AD,. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. Exp Hematol 2005; 33: 1402-16.
33. Zohrabian VM, Forzani B, Chau Z, Murali R, Jhanwar-Uniyal M,. Rho/ROCK and MAPK signaling pathways are involved in glioblastoma cell migration and proliferation. Anticancer Res 2009; 29: 119-23.
34. Enam SA, Rosenblum ML, Edvardsen K,. Role of extracellular matrix in tumor invasion: migration of glioma cells along fibronectin-positive mesenchymal cell processes. Neurosurgery 1998; 42: 599-607.
35. Lazennec G, Jorgensen C,. Concise review: adult multipotent stromal cells and cancer: risk or benefit? Stem Cells 2008; 26: 1387-94.
36. Szatmári T, Lumniczky K, Désaknai S, Trajcevski S, Hídvégi EJ, Hamada H, Sáfrány G,. Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy. Cancer Sci 2006; 97: 546-53.
37. Jungbluth AA, Stockert E, Huang HJ, Collins VP, Coplan K, Iversen K, Kolb D, Johns TJ, Scott AM, Gullick WJ, Ritter G, Cohen L, et al. A monoclonal antibody recognizing human cancers with amplification/overexpression of the human epidermal growth factor receptor. Proc Natl Acad Sci USA 2003; 100: 639-44.